ReviewJACC. CardioOncology2021
Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization.
Review in JACC. CardioOncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Cardiac magnetic resonance with myocardial strain as a predictor of anthracycline-induced cardiotoxicity in patients with lymphoma: a prospective multimodality study.Cardio-oncology (London, England) · 2026Article
- Performance of Traditional Cardiovascular Risk Scores and Objective Optimization in Cancer Survivors.Current oncology (Toronto, Ont.) · 2026Article
- Diagnostics in cardio-oncology: a focus on anthracyclines.Heart failure reviews · 2026Review
- A Discovery of Potentially Hereditary Cardiac Angiosarcoma.JACC. Case reports · 2026Article
- An innovative hybrid imaging protocol for whole-bodyCardio-oncology (London, England) · 2025Article
- Cardiac magnetic resonance imaging in the assessment of cardiac injury and toxicity from cancer-related chemotherapy.Pediatric radiology · 2025Review
- Cardiac Magnetic Resonance in the Evaluation and Management of Nonischemic Cardiomyopathies.JACC. Heart failure · 2025Review
- Acute Myocarditis and Inflammatory Cardiomyopathies: Insights From Cardiac Magnetic Resonance Findings.Echocardiography (Mount Kisco, N.Y.) · 2025Review
- Quantitative assessment of early changes in myocardial extracellular volume during postoperative adjuvant chemotherapy in patients with breast cancer via dual-layer spectral detector computed tomography: a cohort study.Quantitative imaging in medicine and surgery · 2025Article
- Anthracycline Cardiotoxicity in Adult Cancer Patients:JACC. CardioOncology · 2024Review
- Diagnostic and Therapeutic Approaches for Heart Failure in Long-Term Survivors of Childhood Cancer.Biomedicines · 2024Review
- Cancer therapy-related cardiac dysfunction and the role of cardiovascular imaging: systemic review and opinion paper from the Working Group on Cardio-Oncology of the Korean Society of Cardiology.Journal of cardiovascular imaging · 2024Review
- Chemotherapy Related Cardiotoxicity Evaluation-A Contemporary Review with a Focus on Cardiac Imaging.Journal of clinical medicine · 2024Review
- Multi-parameter cardiac magnetic resonance imaging detects anthracycline-induced cardiotoxicity in rabbits model.Heliyon · 2023Article
- Tales from the future-nuclear cardio-oncology, from prediction to diagnosis and monitoring.European heart journal. Cardiovascular Imaging · 2023Review
- Imaging of heart disease in women: review and case presentation.European journal of nuclear medicine and molecular imaging · 2022Review
- Cardio-Oncology Care Delivered in the Non-academic Environment.Current treatment options in oncology · 2022Review
- Machine learning algorithm using publicly available echo database for simplified "visual estimation" of left ventricular ejection fraction.World journal of experimental medicine · 2022Article
- Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Diagnosis of acute and late cardiotoxicity from cancer therapeutics has become increasingly important as the scope of cardio-oncology increases exponentially, both in terms of the number of people affected and the types of therapies it encompasses. Cardiac magnetic resonance (CMR) is a tool that can offer unparalleled diagnostic information compared with other imaging modalities, but its utilization is often delayed, at the expense of patient care, due to the need for insurance pre-authorization. This paper highlights situations in which CMR is preferred as the diagnostic modality and provides examples of diagnoses more likely to be approved by insurance companies. It also provides specific cardio-oncology diagnoses or questions to help the clinical cardio-oncologist navigate the pre-authorization process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.